Any defect in one or more genes that affect the nervous system can lead to a neurogenetic disorder. Neurogenetic testing is a test for neurogenetic disorders such as dementia, inherited neuropathies, Parkinson's disease, epilepsy, and more.
The global market for Neurogenetic Testing was estimated to be worth US$ 477 million in 2023 and is forecast to a readjusted size of US$ 1028.3 million by 2030 with a CAGR of 11.8% during the forecast period 2024-2030
Global key players of neurogenetic testing include Quest Diagnostics, Mayo Clinic, GeneDx, Illumina, Labcorp, etc. The top five players hold a share over 28%. In terms of product type, Exome Sequencing is the largest segment, occupied for a share of 44%, and in terms of application, Hospitals has a share about 46 percent.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neurogenetic Testing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Neurogenetic Testing by region & country, by Type, and by Application.
The Neurogenetic Testing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurogenetic Testing.
Market Segmentation
By Company
Quest Diagnostics
Mayo Clinic
GeneDx
Illumina
Labcorp
Invitae
MedGenome Labs
Connecticut Children’s
CENTOGENE
Victorian Clinical Genetics Services
PacBio
Segment by Type:
Exome Sequencing
Whole Genome Sequencing
RNA Sequencing
General DNA Testing
Segment by Application
Hospitals
Specialty Clinics
Research Institutes
Diagnostics Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Neurogenetic Testing manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Neurogenetic Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Neurogenetic Testing in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Neurogenetic Testing Product Introduction
1.2 Global Neurogenetic Testing Market Size Forecast
1.3 Neurogenetic Testing Market Trends & Drivers
1.3.1 Neurogenetic Testing Industry Trends
1.3.2 Neurogenetic Testing Market Drivers & Opportunity
1.3.3 Neurogenetic Testing Market Challenges
1.3.4 Neurogenetic Testing Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Neurogenetic Testing Players Revenue Ranking (2023)
2.2 Global Neurogenetic Testing Revenue by Company (2019-2024)
2.3 Key Companies Neurogenetic Testing Manufacturing Base Distribution and Headquarters
2.4 Key Companies Neurogenetic Testing Product Offered
2.5 Key Companies Time to Begin Mass Production of Neurogenetic Testing
2.6 Neurogenetic Testing Market Competitive Analysis
2.6.1 Neurogenetic Testing Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Neurogenetic Testing Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurogenetic Testing as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Exome Sequencing
3.1.2 Whole Genome Sequencing
3.1.3 RNA Sequencing
3.1.4 General DNA Testing
3.2 Global Neurogenetic Testing Sales Value by Type
3.2.1 Global Neurogenetic Testing Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Neurogenetic Testing Sales Value, by Type (2019-2030)
3.2.3 Global Neurogenetic Testing Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Specialty Clinics
4.1.3 Research Institutes
4.1.4 Diagnostics Laboratories
4.2 Global Neurogenetic Testing Sales Value by Application
4.2.1 Global Neurogenetic Testing Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Neurogenetic Testing Sales Value, by Application (2019-2030)
4.2.3 Global Neurogenetic Testing Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Neurogenetic Testing Sales Value by Region
5.1.1 Global Neurogenetic Testing Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Neurogenetic Testing Sales Value by Region (2019-2024)
5.1.3 Global Neurogenetic Testing Sales Value by Region (2025-2030)
5.1.4 Global Neurogenetic Testing Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Neurogenetic Testing Sales Value, 2019-2030
5.2.2 North America Neurogenetic Testing Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Neurogenetic Testing Sales Value, 2019-2030
5.3.2 Europe Neurogenetic Testing Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Neurogenetic Testing Sales Value, 2019-2030
5.4.2 Asia Pacific Neurogenetic Testing Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Neurogenetic Testing Sales Value, 2019-2030
5.5.2 South America Neurogenetic Testing Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Neurogenetic Testing Sales Value, 2019-2030
5.6.2 Middle East & Africa Neurogenetic Testing Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Neurogenetic Testing Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Neurogenetic Testing Sales Value
6.3 United States
6.3.1 United States Neurogenetic Testing Sales Value, 2019-2030
6.3.2 United States Neurogenetic Testing Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Neurogenetic Testing Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Neurogenetic Testing Sales Value, 2019-2030
6.4.2 Europe Neurogenetic Testing Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Neurogenetic Testing Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Neurogenetic Testing Sales Value, 2019-2030
6.5.2 China Neurogenetic Testing Sales Value by Type (%), 2023 VS 2030
6.5.3 China Neurogenetic Testing Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Neurogenetic Testing Sales Value, 2019-2030
6.6.2 Japan Neurogenetic Testing Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Neurogenetic Testing Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Neurogenetic Testing Sales Value, 2019-2030
6.7.2 South Korea Neurogenetic Testing Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Neurogenetic Testing Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Neurogenetic Testing Sales Value, 2019-2030
6.8.2 Southeast Asia Neurogenetic Testing Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Neurogenetic Testing Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Neurogenetic Testing Sales Value, 2019-2030
6.9.2 India Neurogenetic Testing Sales Value by Type (%), 2023 VS 2030
6.9.3 India Neurogenetic Testing Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Quest Diagnostics
7.1.1 Quest Diagnostics Profile
7.1.2 Quest Diagnostics Main Business
7.1.3 Quest Diagnostics Neurogenetic Testing Products, Services and Solutions
7.1.4 Quest Diagnostics Neurogenetic Testing Revenue (US$ Million) & (2019-2024)
7.1.5 Quest Diagnostics Recent Developments
7.2 Mayo Clinic
7.2.1 Mayo Clinic Profile
7.2.2 Mayo Clinic Main Business
7.2.3 Mayo Clinic Neurogenetic Testing Products, Services and Solutions
7.2.4 Mayo Clinic Neurogenetic Testing Revenue (US$ Million) & (2019-2024)
7.2.5 Mayo Clinic Recent Developments
7.3 GeneDx
7.3.1 GeneDx Profile
7.3.2 GeneDx Main Business
7.3.3 GeneDx Neurogenetic Testing Products, Services and Solutions
7.3.4 GeneDx Neurogenetic Testing Revenue (US$ Million) & (2019-2024)
7.3.5 Illumina Recent Developments
7.4 Illumina
7.4.1 Illumina Profile
7.4.2 Illumina Main Business
7.4.3 Illumina Neurogenetic Testing Products, Services and Solutions
7.4.4 Illumina Neurogenetic Testing Revenue (US$ Million) & (2019-2024)
7.4.5 Illumina Recent Developments
7.5 Labcorp
7.5.1 Labcorp Profile
7.5.2 Labcorp Main Business
7.5.3 Labcorp Neurogenetic Testing Products, Services and Solutions
7.5.4 Labcorp Neurogenetic Testing Revenue (US$ Million) & (2019-2024)
7.5.5 Labcorp Recent Developments
7.6 Invitae
7.6.1 Invitae Profile
7.6.2 Invitae Main Business
7.6.3 Invitae Neurogenetic Testing Products, Services and Solutions
7.6.4 Invitae Neurogenetic Testing Revenue (US$ Million) & (2019-2024)
7.6.5 Invitae Recent Developments
7.7 MedGenome Labs
7.7.1 MedGenome Labs Profile
7.7.2 MedGenome Labs Main Business
7.7.3 MedGenome Labs Neurogenetic Testing Products, Services and Solutions
7.7.4 MedGenome Labs Neurogenetic Testing Revenue (US$ Million) & (2019-2024)
7.7.5 MedGenome Labs Recent Developments
7.8 Connecticut Children’s
7.8.1 Connecticut Children’s Profile
7.8.2 Connecticut Children’s Main Business
7.8.3 Connecticut Children’s Neurogenetic Testing Products, Services and Solutions
7.8.4 Connecticut Children’s Neurogenetic Testing Revenue (US$ Million) & (2019-2024)
7.8.5 Connecticut Children’s Recent Developments
7.9 CENTOGENE
7.9.1 CENTOGENE Profile
7.9.2 CENTOGENE Main Business
7.9.3 CENTOGENE Neurogenetic Testing Products, Services and Solutions
7.9.4 CENTOGENE Neurogenetic Testing Revenue (US$ Million) & (2019-2024)
7.9.5 CENTOGENE Recent Developments
7.10 Victorian Clinical Genetics Services
7.10.1 Victorian Clinical Genetics Services Profile
7.10.2 Victorian Clinical Genetics Services Main Business
7.10.3 Victorian Clinical Genetics Services Neurogenetic Testing Products, Services and Solutions
7.10.4 Victorian Clinical Genetics Services Neurogenetic Testing Revenue (US$ Million) & (2019-2024)
7.10.5 Victorian Clinical Genetics Services Recent Developments
7.11 PacBio
7.11.1 PacBio Profile
7.11.2 PacBio Main Business
7.11.3 PacBio Neurogenetic Testing Products, Services and Solutions
7.11.4 PacBio Neurogenetic Testing Revenue (US$ Million) & (2019-2024)
7.11.5 PacBio Recent Developments
8 Industry Chain Analysis
8.1 Neurogenetic Testing Industrial Chain
8.2 Neurogenetic Testing Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Neurogenetic Testing Sales Model
8.5.2 Sales Channel
8.5.3 Neurogenetic Testing Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Quest Diagnostics
Mayo Clinic
GeneDx
Illumina
Labcorp
Invitae
MedGenome Labs
Connecticut Children’s
CENTOGENE
Victorian Clinical Genetics Services
PacBio
*If Applicable.